Phase 3 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 50 or older at the time of screening
- People who have been diagnosed with probable Alzheimer's disease using recognised medical guidelines, supported by brain scans (CT or MRI) and blood tests done as part of routine care
- People whose score on a standard memory and thinking test (called the MMSE) is 16 or higher
- People who have an informant or carer who lives with them and can provide information about their condition
- People who are either not taking Alzheimer's medications, or who have been on a stable dose of those medications for at least 2 months before the study begins and can remain on that stable dose throughout the study
Who may not be able to join:
- People who are unwilling to follow a low-caffeine diet, which means avoiding tea, caffeinated soft drinks, and large amounts of chocolate
- People currently experiencing a major depressive episode, as defined by recognised diagnostic criteria
- People who have another long-term condition affecting the brain or nervous system
- People assessed by their doctor as having severe anxiety, based on specific scoring thresholds on a standard assessment tool
- People with sleep disorders of significant severity and impact, as measured by a standard assessment tool — though people being treated for obstructive sleep apnoea may still be considered if their treatment device has been used consistently for at least 3 months and is well tolerated
- People with serious heart disease or a significant heart rhythm disorder (note: slow, treated, and stable chronic irregular heartbeat may not be a barrier — confirm with trial site)
- People who currently smoke
- Women who are pregnant or planning to become pregnant (a pregnancy test will be carried out)
- People taking certain medications, including: psychiatric or mental health medications that were started or changed less than 2 months before joining; certain drugs that affect how the liver processes substances (CYP1A2 inducers or inhibitors — confirm with trial site); any medications or products containing caffeine; or any drugs that interact with caffeine
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: thibaud LEBOUVIER, MD,PhD, University Hospital, Lille
Phone: 03 20 44 60 21
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Changes in NTB scores
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.